At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XERS Xeris Pharmaceuticals Inc
Market Closed 05-17 16:00:00 EDT
1.98
-0.04
-1.98%
盘后1.99
+0.01+0.51%
19:59 EDT
High2.07
Low1.96
Vol1.24M
Open2.04
D1 Closing2.02
Amplitude5.45%
Mkt Cap293.55M
Tradable Cap285.31M
Total Shares148.26M
T/O2.49M
T/O Rate0.86%
Tradable Shares144.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Xeris Enters Into An Exclusive Worldwide Collaboration And License Agreement With Beta Bionics
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.